Earnings reports are critical indicators of a company's financial health and often have a direct impact on stock prices. Lantern Pharma's worse-than-expected Q1 GAAP EPS results suggest underperformance compared to market expectations, which typically leads to a negative investor reaction and a decrease in share price in the short term.